undertaken to test the effectiveness of oral hypoglycaemic drugs in improving blood glucose and plasma insulin levels of borderline diabetic patients. Between 1969 and 1971, 120 men aged 25 to 55 with borderline impairment of glucose tolerance according to standard criteria at 2 successive oral glucose tolerance tests entered the study. They were randomized into 4 groups according to treatment: dimethylbiguanide + glibenclamide (n = 29), placebo B + glibenclamide (n = 28), placebo S + dimethylbiguanide (n = 30), placebo B + S (n --33). In each group drugs were taken twice a day before breakfast and lunch at a total dosage of 1.7 g/ day dimethylbiguanide and/or 4 rag/day glibenclamide. Treatment was stopped after 2 years. Patients returned 2 months after entry into the trial, then every 4 months for 2 years. Treatment was continued up to each oral glucose tolerance test except before the last test (drugs stopped 15 days before). 29 patients weighed 20% or more over their ideal body weight and 23 between 10% and 20%. After a dietary survey, these men were subjected to a total colorie restricted diet according to their excess weight. Results indicate that during the 2 years of treatment, no significant lasting effect of the biguanide on blood glucose and plasma insulin levels was detectable. During the oral glucose tolerance test at 14 months in the groups receiving sulphonylurea a significant decrease of blood glucose levels was observed at 0, 180 and 240 min. Glibenclamide had no effect on weight reduction while biguanide administration was accompanied by a significant weight reduction. * Parts of this paper were presented at the 10th meeting of the EASD in Jerusalem and published in abstract form in Diabetologia 10, 363 (1974) Key words: Randomized clinical trial, borderline diabetes, oral hypoglycaemic drugs, glucose tolerance, insulin secretion, dimethylbiguanide, sulphonylurea.
Summary. A double blind controlled clinical trial was
undertaken to test the effectiveness of oral hypoglycaemic drugs in improving blood glucose and plasma insulin levels of borderline diabetic patients. Between 1969 and 1971, 120 men aged 25 to 55 with borderline impairment of glucose tolerance according to standard criteria at 2 successive oral glucose tolerance tests entered the study. They were randomized into 4 groups according to treatment: dimethylbiguanide + glibenclamide (n = 29), placebo B + glibenclamide (n = 28), placebo S + dimethylbiguanide (n = 30), placebo B + S (n --33). In each group drugs were taken twice a day before breakfast and lunch at a total dosage of 1.7 g/ day dimethylbiguanide and/or 4 rag/day glibenclamide. Treatment was stopped after 2 years. Patients returned 2 months after entry into the trial, then every 4 months for 2 years. Treatment was continued up to each oral glucose tolerance test except before the last test (drugs stopped 15 days before). 29 patients weighed 20% or more over their ideal body weight and 23 between 10% and 20%. After a dietary survey, these men were subjected to a total colorie restricted diet according to their excess weight. Results indicate that during the 2 years of treatment, no significant lasting effect of the biguanide on blood glucose and plasma insulin levels was detectable. During the oral glucose tolerance test at 14 months in the groups receiving sulphonylurea a significant decrease of blood glucose levels was observed at 0, 180 and 240 min. Glibenclamide had no effect on weight reduction while biguanide administration was accompanied by a significant weight reduction.
Prospective studies in man [1] [2] [3] and animals [4] [5] [6] support the concept that optimal control of blood glucose level delays the development of microvascular lesions in overt diabetes. Lowering blood glucose levels in borderline diabetic patients, then, appears a logical aim of treatment in order to achieve early prevention of degenerative vascular changes. We have therefore investigated the effectiveness of oral hypoglycaemic drugs on the glucose and insulin responses to an oral glucose load in patients with borderline impairment of glucose tolerance [7] , in a controlled clinical trial.
Material and Methods

Oral Glucose Tolerance Test
Because of the variability in carbohydrate tolerance at successive examinations [8] [9] [10] [11] [12] , a two step procedure was employed to test eligibility of patients:
1. At the first test venous blood glucose concentration fasting was measured, (BGo) and 2 h (BG2) after a 75 g oral glucose load, by a glucose -oxidase method [13] . The subjects were classified according to the European Diabetes Epidemiology Study Group (EDESG) criteria [14-15]: when BGo was lower than 100 mg/ 100 ml and BG2 lower than 120 mg/I00 ml the subject was considered normal, when BG o was equal to 130 mg/100 ml or more and BG 2 equal to 150 mg/100 ml or more, the subject was considered diabetic. All remaining subjects were classified borderline and submitted to the second test.
2. The second test was performed 8 to 15 days later under standard conditions [16] with, in particular, dietary preparation Table 1 . Distribution of 120 eligible subjects according to 6 different criteria [20] applied to the 5 h OGTT results
The subjects are recognized as:
Normal
Diabetic Borderline
British Diabetic Association criteria [19] . None of the subjects would be recognized as normal by all criteria, while 7% of them would be universally recognized as diabetic. These results show the discrepancy between the different criteria as emphasized in another study [20] . According to these criteria, the subjects were classified as follows: all subjects with normal responses at the four times were excluded as well as the subjects with both BG o and BG120 diabetic responses. Among the remainder, eligible subjects were either those with BG120 equal to or greater than 120 mg/100 ml or else those with BG o, BG30 and BG60 all equal to or greater than their respective limits 11 .
These criteria were established prior to the beginning of the trial according to the experience of 7 diabetologists in order to exclude any subject for whom they judged there was no possible choice between treatment and placebo [17] .
Patients
One hundred and twenty patients were recruited from among the male population spontaneously asking medical advice in a screening centre for Diabetes at the Hotel Dieu Hospital in Paris, between March 1969 and October 1971. They were 25 to 55 years old, free from any other apparent clinical disease, and taking no drugs. 29 (25%) of them were 20% or more over their ideal body weight and 23 (19%) between 10% and 20%. Thirty four patients (24 during the first year, 10 during the second year of the study) were lost to follow-up; they came equally from the four different treatment groups and exhibited similar baseline characteristics to the follow-up patients. Their removal from the trial did not introduce any bias into the study. To judge the inclusion criteria previously defined the 120 subjects selected for the trial were classified according to 6 different international criteria regarding their 5 h OGTF results (Table 1) . In the study sample, 83% were normal according to the Wilkerson point system [18] whereas only 26% were normal according to the
Allocation to Treatment
Based upon sequence of entry to the study, patients in each group were assigned a trial number. This determined the treatment they received, but the trial number gave no indication of the treatment. Randomization with equal numbers of patients in each treatment group was carried out.
Treatment
Four treatment groups were studied:
I. Sulphonylurea-treated group (S group) who received 2 mg of Glibenclamide and a biguanide placebo before breakfast and before lunch.
2. The biguanide-treated group (B) received 0.85g of dimethylbiguanide and a sulphonylurea placebo before breakfast and before lunch.
3. Combined therapy group (B + S) who received both drugs in the above doses.
4. The placebo group (P) who received a sulphonylurea placebo and a biguanide placebo.
Tablets were taken every day for the 2 years of the trial. None of the patients under study exhibited symptoms of intolerance requiring a change of therapy. Fourteen patients, equally distributed in the four groups, admitted to having stopped their drug intake for 1 month or less.
All patients were regularly questioned on their dietary habits. Overweight patients were prescribed calorie restriction in order to approach their ideal body weight [21] . The diet was aimed at restricting firstly, alcohol consumption, then sweets and pastries, then extra fats, such as butter and oil, and finally bread if necessary. In all cases, the balance between the different nutrients was respected.
Data Collection
Every four months, clinical and biochemical examinations were performed. In practice, none of the patients exhibited any pathological symptom during the survey. Oral glucose tolerance tests were performed 2, 14 and 26 months after the baseline test (i. e. 2nd test for eligibility) as defined above. At 2 and 14 months, the patients received their tablets before the oral glucose tolerance test. Then the treatments were stopped 15 days before the 26 months test. Besides blood glucose measurements, plasma insulin levels were estimated by radioimmunoassay [22] .
Statistical Analysis
The study was designed for two way analysis of variance [23] . Thus, the inclusion of the four possible combinations of treatments into the study allowed us to test if:
1. the effect of biguanides was the same whether sulphonylureas were given at the same time or not, 2. the effect of sulphonylureas was the same whether biguanides were given at the same time or not (test of interaction).
Absence of significant interaction allowed the biguanide effect to be tested by the comparison of both group B with group P, and of group B + S with group S: and, similarly, to test the effect of the 
Results
Baseline Characteristics
Comparison of the four groups was performed for each baseline characteristic (clinical table 2;  biochemical table 3) . No significant difference between the 4 groups was observed; this indicates the effectiveness of the randomisation.
Body Weight
Mean changes in weight are shown for the 4 groups in figure 1 . Weight reduction was observed in each group, placebo group included. All these reductions were significantly different from zero by Student's t-test. Moreover, the comparisons with the placebo group showed at 6 months a greater weight loss in the 2 groups receiving biguanide. The weight loss was smaller in the S group than in the P group, differences reaching a significant level at 22 and 26 months.
Results of the two way analysis of variance are shown in Table 4 . At 6 months and afterwards body weight was significantly lower in the B and B + S groups than in the P and S groups. No significant Table 4 . Effect of biguanide (B) and sulphonylurea (S) on body weight (kg). Group "with B" includes B and B + S -group "without B" includes P and S. Group "with S" includes S and B + S -group "without S" includes P and B. Values represent mean +_ SEM; NS = Differences not significant. Number of subjects is indicated in parenthesis
Group
Time of examinations (in months from baseline) difference, however, was observed between the S and B + S groups when compared to B and P groups.
Blood Glucose
Mean values of blood glucose levels at the successive 5 h OGTT are indicated in Tables 5 and 6 . No significant effect of dimethylbiguanide could be detected at any time in the course of the trial. In the groups receiving glibenclamide (S and B + S), blood glucose mean values were generally lower at the 14 months examination than in the groups without S (P and B). The 5% level of significance was reached for observed differences at fasting, 180 and 240 min after glucose. But at the 2 and 26 months examinations, there was no significant difference. Tables 7 and 8 show the failure of glibenclamide and  dimethylbiguanide to modify plasma insulin level under the test conditions.
Plasma Insulin
Insulin Glucose Relationships
They were evaluated by the slope of insulin on glucose regression line calculated for each individual OGq'T [12] . Sulphonylurea and biguanide had no apparent effect on these relationships (Table 9 ). 
Efficiency of the Experiment
In order to investigate if the absence of significant effect of treatments on blood glucose could be due to a lack of power of the study test, theoretical differences which would have been significant with a probability equal to 0.95 were calculated. An example of these minimal differences is indicated for 2 months in table 10. They are small enough to be reasonably expected if the therapies used were minimally efficient. 
Discussion
In the present study, sulphonylurea had no effecteven an adverse effect -on weight reduction, while administration of biguanide is accompanied by weight reduction, in accordance with the results reported by Feldman [24] and Clarke [36] . Blood glucose improvement was only observed in the S group at the 14 months test. A significant level was reached only at fasting and at 180 and 240 min after oral glucose. Under the null hypothesis (i. e. no effect) the probability of observing three significant differences of identical sign among the 48 involved comparisons was equal to 11%. Under the alternative hypothesis (i. e. efficacy of drugs as defined in table 10), the probability of obtaining only three significant differences was near zero. So there was no evidence of the effectiveness of oral hypoglycaemic drugs either in lowering blood glucose or in improving insulin secretion in borderline diabetic patients. These results are also in agreement with Feldman's study [24] . However, some differences which might These values are given to appreciate the efficiency of the study. For instance, let be 21 rag/100 ml the true difference (unknown) due to treatment at 120 min after glucose. In this study, with the number of subjects examinated at 2 months, the probability to observe a significant difference was equal to 95%. In the same conditions, a true difference equal to 11 mg/100ml had only a probability of 50% to be detected have interfered with the results are notable between these two trials. Among them are the different patterns of drug intake before the test: in Feldman's study treatments were discontinued 3 days before each OGTI" showing the absence of a permanent effect of drugs on glucose tolerance. In the present study, drugs were not discontinued before the tests except before the last test. Nevertheless no striking effectiveness of the drugs in lowering blood glucose was shown, although the overall procedure of the trial was accurate enough to disclose small differences between the groups. This is of interest because the doses of drugs we used were similar to those usually given in asymptomatic diabetes. In the present study, a sulphonylurea-biguanide association previously advocated [25] could be tested and was found to lack totally any synergic effect on blood glucose. There was no evidence of a significant effect of drugs on insulin levels and the insulin-glucose relationship evaluated by an index currently used [26] [27] was not altered by drugs. Thus, in a long-term experiment, biguanide was not able to diminish plasma insulin level, and sulphonylurea had no apparent stimulatory effect on insulin secretion. This failure of sulphonylurea to increase insulin secretion under chronic administration has been previously demonstrated by CHU et al. [28] and emphasized by PROUT [29] .
This study shows that there is no clear beneficial effect of oral hypoglycaemic drugs on blood glucose levels in borderline diabetics confirming previous findings [37, 24] . In view of the disturbing UGDP [30] [31] [32] findings which suggested a possible toxic effect of oral hypoglycaemic drugs, our results support the concept that there is no rational basis for the use of those agents in patients with mild impairment of glucose tolerance [33] .
